Bio-Thera Secures FDA Approval For Sandoz-Partnered Bevacizumab Biosimilar

Avzivi Is The Second Bio-Thera Biosimilar – And The Second Chinese Biosimilar – To Secure FDA Approval

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.

Hands emblazoned with US and China flags about to shake
Bio-Thera has developed both biosimilars researched, developed and manufactured by a Chinese company to recieve US FDA approval • Source: Shutterstock

Chinese biosimilar developer Bio-Thera Solutions Ltd. has received approval from the US Food and Drug Administration for its Avastin (bevacizumab) biosimilar Avzivi (bevacizumab-tnjn). The drug has already been approved in China since November 2021, as well as in other Asian countries.

Key takeaways:

  • The FDA has approved Bio-Thera’s bevacizumab biosimilar, which will be marketed in the US as Avzivi

Avzivi is both Bio-Thera’s second FDA-approved product and the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.